Third Rock debuts immunometabolism startup Rheos with $60M launch round
Third Rock is pushing one of its stealthy startups into the limelight this morning, with $60 million in fresh capital and a platform tech that operates in the increasingly popular field of immunometabolism.
The startup, called Rheos Medicines, has a drug discovery tech that’s already churned out two leads for the company that are both moving into preclinical development.
Rheos, founded last summer, is digging into the new field of immunometabolism, which basically tries to understand — and later harness — how a cell’s metabolism affects disease progression.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.